Skip to main content

Advertisement

Log in

Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system

  • Gastrointestinal
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

Objectives

To evaluate how sarcomatoid carcinomas (SCs) would be classified on magnetic resonance imaging (MRI) by using the Liver Imaging Reporting and Data System (LI-RADS) and to assess imaging features of SC compared with other hepatic malignancies.

Methods

We retrieved 184 patients with pathologically confirmed SC (n = 46), hepatocellular carcinoma (HCC, n = 92), and intrahepatic cholangiocarcinoma (iCCA, n = 46) diagnosed between January 2006 and December 2017. Two readers independently reviewed MRI according to LI-RADS v2017. Classification rate of SC, as probably or definitely malignant but not specific for HCC (LR-M), was calculated. LR-TIV (tumor in vein) was subclassified as either 5V or MV. MRI features were compared between SC, HCC, and iCCA and between SC of LR-M and non-LR-M categories.

Results

Chronic liver disease was present in 71.7% (33/46) of patients with SC, and LI-RADS was applied for these patients. SC was classified as LR-M in 24 (72.7%) of 33 patients at risk. SCs that had been classified as LR-4/5/5V were significantly smaller (median, 1.9 cm; range, 1.0–4.2 cm) than SCs classified as LR-M/MV (median, 4.3 cm; range, 1.3–20.6 cm) on independent t test (p = 0.012). SCs commonly showed MRI features similar to iCCAs than to HCCs. Targetoid appearance and capsular retraction were more frequent in iCCA than in SC (p ≤ 0.009) on Pearson’s chi-squared test or Fisher’s exact test.

Conclusion

Most SCs can be classified as LR-M on MRI, but small lesions may be indistinguishable from HCCs.

Key Points

• Most sarcomatoid carcinomas (SCs) are classified as LR-M on MRI by using LI-RADS v2017.

• SC showed various LR-M features similar to those of intrahepatic cholangiocarcinoma.

• Size of LR-4/5/5V SC was significantly smaller than that of LR-M/MV SC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

CLD:

Chronic liver disease

DWI:

Diffusion-weighted imaging

HBP:

Hepatobiliary phase

HCC:

Hepatocellular carcinoma

iCCA:

Intrahepatic cholangiocarcinoma

LI-RADS:

Liver Imaging Reporting and Data System

MRI:

Magnetic resonance imaging

SC:

Sarcomatoid carcinoma

T1WI:

T1-weighted imaging

T2WI:

T2-weighted imaging

TIV:

Tumor in vein

References

  1. Kakizoe S, Kojiro M, Nakashima T (1987) Hepatocellular carcinoma with sarcomatous change. Clinicopathologic and immunohistochemical studies of 14 autopsy cases. Cancer 59:310–316

    Article  CAS  PubMed  Google Scholar 

  2. Giunchi F, Vasuri F, Baldin P, Rosini F, Corti B, D’Errico-Grigioni A (2013) Primary liver sarcomatous carcinoma: report of two cases and review of the literature. Pathol Res Pract 209:249–254

    Article  PubMed  Google Scholar 

  3. Fred TB, Fatima C, Ralph HH, Neil DT (2010) WHO classification of tumours of the digestive system. IARC press, Lyon

    Google Scholar 

  4. Nishi H, Taguchi K, Asayama Y et al (2003) Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol 18:415–423

    Article  PubMed  Google Scholar 

  5. Hwang S, Lee SG, Lee YJ et al (2008) Prognostic impact of sarcomatous change of hepatocellular carcinoma in patients undergoing liver resection and liver transplantation. J Gastrointest Surg 12:718–724

    Article  PubMed  Google Scholar 

  6. Kaibori M, Kawaguchi Y, Yokoigawa N et al (2003) Intrahepatic sarcomatoid cholangiocarcinoma. J Gastroenterol 38:1097–1101

    Article  PubMed  Google Scholar 

  7. Lu J, Xiong XZ, Li FY et al (2015) Prognostic significance of sarcomatous change in patients with hepatocellular carcinoma after surgical resection. Ann Surg Oncol 22(Suppl 3):S1048–S1056

    Article  PubMed  Google Scholar 

  8. Liao SH, Su TH, Jeng YM et al (2018) Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology. https://doi.org/10.1002/hep.30162

  9. Gu KW, Kim YK, Min JH, Ha SY, Jeong WK (2017) Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Abdom Radiol (NY) 42:1424–1433

    Article  Google Scholar 

  10. Koo HR, Park MS, Kim MJ et al (2008) Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr 32:745–749

    Article  Google Scholar 

  11. Honda H, Hayashi T, Yoshida K et al (1996) Hepatocellular carcinoma with sarcomatous change: characteristic findings of two-phased incremental CT. Abdom Imaging 21:37–40

    Article  CAS  Google Scholar 

  12. Bilgin M, Toprak H, Bilgin SS, Kondakci M, Balci C (2012) CT and MRI findings of sarcomatoid cholangiocarcinoma. Cancer Imaging 12:447–451

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chung YE, Park MS, Park YN et al (2009) Hepatocellular carcinoma variants: radiologic-pathologic correlation. AJR Am J Roentgenol 193:W7–W13

    Article  PubMed  Google Scholar 

  14. Shi D, Ma L, Zhao D et al (2018) Imaging and clinical features of primary hepatic sarcomatous carcinoma. Cancer Imaging 18:36

    Article  PubMed  PubMed Central  Google Scholar 

  15. American College of Radiology. Liver imaging reporting and data system (LI-RADS). American College of Radiology. Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. Accessed June 1, 2017

  16. Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380

    Article  Google Scholar 

  17. European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236

    Article  Google Scholar 

  18. Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology 61:1056–1065

    Article  Google Scholar 

  19. An C, Rhee H, Han K et al (2017) Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol 27:2610–2618

    Article  Google Scholar 

  20. Seo N, Kim DY, Choi JY (2017) Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis. AJR Am J Roentgenol 209:W64–w75

    Article  PubMed  Google Scholar 

  21. Ariizumi S, Kotera Y, Takahashi Y et al (2011) Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase computed tomography reflects favorable surgical outcomes. J Surg Oncol 104:130–139

    Article  PubMed  Google Scholar 

  22. Kim SJ, Lee JM, Han JK, Kim KH, Lee JY, Choi BI (2007) Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189:1428–1434

    Article  PubMed  Google Scholar 

  23. Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK (2016) Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging 44:1330–1338

    Article  Google Scholar 

  24. Kim YY, An C, Kim S, Kim MJ (2018) Diagnostic accuracy of prospective application of the liver imaging reporting and data system (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol 28:2038–2046

    Article  PubMed  Google Scholar 

  25. Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology 286:158–172

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Ha Yan Kim for her help with the statistical advice.

Funding

The authors state that this work has not received any funding.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Myeong-Jin Kim.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Myeong-Jin Kim.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

Nieun Seo performed statistical analysis, who is one of the coauthors. Ha Yan Kim, Ph.D., who is a member of our biostatistics collaboration unit, Yonsei University College of Medicine, gave us advice on the statistical analysis.

Informed consent

Written informed consent was waived by the Institutional Review Board for this retrospective case-control study.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seo, N., Kim, MJ. & Rhee, H. Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol 29, 3761–3771 (2019). https://doi.org/10.1007/s00330-019-06052-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-019-06052-8

Keywords

Navigation